Series C
Capital Raise
November 2016

Company Overview

  • Vapogenix is a clinical stage company developing a new class of analgesics based on formulations of volatile anesthetics to treat a variety of localized painful conditions
  • Their pipeline includes:
  • AWARD- a topical analgesic used to reduce wound pain associated with ulcerous, traumatic wounds and burns
  • RAFT- a quick acting topical analgesic for use on intact skin and mucous membranes, with much faster onset of action than competing lidocaine- based products
  • TAIM- targets alleviating localized inflammatory and muscular pain

Value Provided by Frontcourt

  • Engaged to raise Series C Funding Round to continue clinical development and initiate commercialization
  • Advised on amount of need/raise
  • Assisted in creation of focused clinical and commercial strategy
  • Created and implemented a Public Relations strategy
  • Managed inbound strategic M&A interest
  • Introduced leading pain management KOLs
  • Introduced key contacts at several potential customer accounts including the VA
  • Frontcourt identified and structured participation from value-added investors including a major participation from a billion-dollar family office
  • Identified and introduced value added Board Members

We want to work with you

We can't wait to meet you. Hear your story. Connect.

Contact Us